Suraksha Diagnostic Share Price

Suraksha Diagnostic Limited was incorporated as Suraksha Diagnostic Private Limited as a private limited company dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata. Subsequently, Company was converted into a public limited company and the name of Company was changed to Suraksha Diagnostic Limited, and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre. The Company is mainly engaged in running diagnostic centres for carrying out various pathological and radiological testing and medical consultation services in in East India. In addition to integrated pathology and radiology testing services, it also offer omnichannel medical consultation services via online and offline modes to customers through 43 of its diagnostic centres which house 120 polyclinic chambers hosting 750+ doctors. The diagnostic test menu included (a) 788 routine pathology tests ranging from basic biochemistry andhematology to 647 specialized pathology tests such as advanced biochemistry, histopathology, and molecular pathology, and (b) 748 basic/intermediate radiology tests ranging from basic xrays, ultrasonography (USG), and computerized tomography (CT) scans to 104 advanced radiology tests such as magnetic resonance imaging (MRI) scans and specialized CT scans.The diagnostic centre was initially operated under the Group Company, Suraksha Diagnostic and Eye Centre Private Limited, which was later acquired by the Company in 2005. The first centre of the Company was launched at Kestopur in 2007. The second centre launched at Khardah in 2010, which increased the operating centres to 5. The Company increased the laboratories to 4 and the operating centres rose to 25 in 2016. The Company further acquired the business of Sunwell Diagnostic Private Limited in 2017. The operations to Meghalaya were expanded through a publicprivate partnership with the Government of Meghalaya in 2019. Further, 2 preexisting diagnostic centres in Kolkata were acquired by the Company from Future Medical and Research Trust in 2020. And the first 3T MRI and 128 CT launched at New Town in 2023. The Company launched the IPO by raising Rs 846.25 Crore equity shares with the issuance of 19,189,330 equity shares of face value of Rs 2 through offer for sale in December, 2024. The Company acquired 63% stake in Fetomat Wellness Private Limited on April 9, 2025, marking its entry into the field of genomic medicine in FY 2025. It added 7 new centres to the network under the Public Private Partnership (PPP) model. With these additions, the network grew to 55 centres as of March, 2025.

Suraksha Diagnostic reported a Q1 FY 2025-26 revenue of ₹78.73 crore, up 15.2% YoY, with net profit increased 33.9% to ₹8.83 crore. For the full year FY2025–2026, revenue reached ₹255.94 crore and profit touched at ₹30.98 crore. As of Sep '25, Suraksha Diagnostic’s market capitalisation stood at ₹1,422.59 crores. Shareholding as of Sep '25 shows promoters holding 49%, with FIIs at 13.7%, DIIs at 22%, and public at 15.3%.

As of 19 Dec 2025, Suraksha Diagnostic share price is ₹271.6. The stock opened at ₹278.6 and had closed at ₹273.2 the previous day. During today’s trading session, Suraksha Diagnostic share price moved between ₹271.00 and ₹278.60, with an average price for the day of ₹274.80. Over the last 52 weeks, the stock has recorded a low of ₹231.00 and a high of ₹421.95. In terms of performance, Suraksha Diagnostic share price has declined by 16.1% over the past six months and has declined by 31.05% over the last year.